Cytokinetics (CYTK) PT Raised at RBC Capital into Aficamten 2026 Launch
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev raised the price target on Cytokinetics (NASDAQ: CYTK) to $87.00 (from $82.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
